Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;12(1):3525-3538.
doi: 10.1080/21655979.2021.1950282.

Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p

Dijian Shen  1   2 , Jianqiang Li  1   2 , Kaiyi Tao  1   2 , Youhua Jiang  1   2
Affiliations

Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p

Dijian Shen et al. Bioengineered. 2021 Dec.

Abstract

Lung cancer (LC) ranks first among all causes of cancer-related death, with non-small cell lung cancer (NSCLC) taking up 85% of lung cancer cases. Although lncRNA MCM3AP antisense RNA 1 (MCM3AP-AS1) has been reported to be an oncogenic factor in NSCLC, its detailed mechanism in NSCLC is unknown. In this study, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to determine MCM3AP-AS1, microRNA (miR)-195-5p and E2F transcription factor 3 (E2F3) mRNA expressions in NSCLC tissues and cells. Western blot was utilized to determine the expression levels of E2F3, BCL2-associated X protein (Bax), B-cell lymphoma-2 (Bcl-2), E-cadherin and N-cadherin. CCK-8 and Transwell assays were conducted to examine cell proliferation, migration and invasion, respectively. Dual-luciferase reporter assay and RNA immunoprecipitation experiments were used to determine the regulatory relationships between MCM3AP-AS1 and miR-195-5p, and miR-195-5p and E2F3. We demonstrated that MCM3AP-AS1 was overexpressed in NSCLC tissues and cells, and MCM3AP-AS1 overexpression accelerated the proliferation, migration and invasion of NSCLC cells. In addition, MCM3AP-AS1 overexpression markedly up-modulated Bcl-2 expression and repressed Bax expression; MCM3AP-AS1 overexpression also significantly up-regulated N-cadherin expression and suppressed E-cadherin expression in NSCLC cells. What is more, in NSCLC cells, miR-195-5p was a target of MCM3AP-AS1, and the latter worked as a molecular sponge for miR-195-5p to regulate E2F3 expression. Collectively, MCM3AP-AS1, serving as a competitive endogenous RNA (ceRNA) to regulate miR-195-5p/E2F3 axis, promotes NSCLC progression, which is a promising therapeutic target for NSCLC.

Keywords: E2F3; MCM3AP-AS1; NSCLC; miR-195-5p.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Expression of MCM3AP-AS1, miR-195-5p and E2F3 in NSCLC
Figure 2.
Figure 2.
MCM3AP-AS1 was specifically regulated by miR-195-5p
Figure 3.
Figure 3.
Effect of MCM3AP-AS1 and miR-195-5p on A549 and H226 cells proliferation and apoptosis
Figure 4.
Figure 4.
Effect of MCM3AP-AS1 on NSCLC cell migration and invasion
Figure 5.
Figure 5.
MCM3AP-AS1 up-regulated E2F3 expression by adsorbing miR-195-5p
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shen DJ, Jiang YH, Li JQ, et al. A-binding protein RBM47 inhibits non-small cell lung carcinoma metastasis through modulation of AXIN1 mRNA stability and Wnt/β-catentin signaling. Surg Oncol. 2020. Sep;34:31–39. - PubMed
    1. Gelatti ACZ, Drilon A, Santini FC.. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113–122. - PMC - PubMed
    1. Wang H, Yu X, Fan Y, et al. Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer. Oncol Targets Ther. 2018;11:2149–2155. - PMC - PubMed
    1. Jiang YH, Xu XL, Ruan HH, et al. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer. Med Oncol. 2014;31(5):959. - PubMed
    1. Kanda S, Ohe Y, Goto Y, et al. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Cancer Sci. 2020;111(6):1933–1942. - PMC - PubMed